Your maths may be correct, but I’m not sure your assumptions are.
According to Acadia, there are 4500 diagnosed individuals with Rett syndrome in the United States.
One of the basic requirements to qualify for health coverage of Daybue is a diagnosis of Rett.
If 75% of the currently diagnosed US Rett population gave Daybue a go, at an average cost of $375,000 per annum, that would be $1.266bn a year. But a dropout rate of 25% (which seems to reflect the real world persistency rate to date) would bring that figure back to $949m, still shy of the $1bn mark.
Of course, increasing the diagnosed US population (which I am sure Acadia is working hard on) as well as adding Canadian Rett patients could boost this figure further.
Share Price, page-7949
-
- There are more pages in this discussion • 2,791 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.22 |
Change
0.240(1.20%) |
Mkt cap ! $2.584B | |||
| Open | High | Low | Value | Volume |
| $20.11 | $20.34 | $19.63 | $8.874M | 441.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1010 | $20.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.23 | 1443 | 2 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |